From ICI to ICU: Ipilimumab and Nivolumab-Induced Immune Checkpoint Inhibitor Colitis.

Autor:	Zhou, Wendy, Frye, Joseph, Soroudi, Camille, Triadafilopoulos, George, Berry, Rani
Předmět:	IMMUNE checkpoint inhibitors COLITIS INFLAMMATORY bowel diseases ISCHEMIC colitis IPILIMUMAB CROHN'S disease
Zdroj:	Digestive Diseases & Sciences; Mar2022, Vol. 67 Issue 3, p800-803, 4p
Abstrakt:	Discussion This patient received 2 cycles of ipilimumab and nivolumab for RCC recurrence and subsequently developed grade 2 ICI colitis, which ultimately progressed to fulminant colitis despite treatment with infliximab and multiple courses of steroids. A colonoscopy with biopsy is the "gold standard" used to diagnose ICI colitis, which endoscopically usually appears as areas of focal or diffuse inflammation that must be pathologically differentiated from other conditions such as inflammatory bowel disease or CMV colitis. Prior reports have noted endoscopic features of ICI colitis that are often steroid-refractory, warranting infliximab use, including pancolitis or colonic ulcers [[6]], both present in our patient. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink